Načítá se...
Tocilizumab: An Effective Therapy for Severely and Critically Ill COVID-19 Patients
Background: Tocilizumab (TCZ), a monoclonal antibody against the most prevalent cytokine interleukin-6 (IL-6), is an emerging therapeutic option for COVID-19 infections. The present study was undertaken to assess the therapeutic response of TCZ therapy in severely or critically ill COVID-19 patients...
Uloženo v:
| Vydáno v: | Indian J Crit Care Med |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Jaypee Brothers Medical Publishers
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7991771/ https://ncbi.nlm.nih.gov/pubmed/33790504 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5005/jp-journals-10071-23747 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|